Synonym
BP-1.137; BP 1.137; BP1.137; BP-1137; BP 1137; BP1137; Fasidotril
IUPAC/Chemical Name
benzyl ((S)-3-(acetylthio)-2-(benzo[d][1,3]dioxol-5-ylmethyl)propanoyl)-L-alaninate
InChi Key
KKBIUAUSZKGNOA-HNAYVOBHSA-N
InChi Code
InChI=1S/C23H25NO6S/c1-15(23(27)28-12-17-6-4-3-5-7-17)24-22(26)19(13-31-16(2)25)10-18-8-9-20-21(11-18)30-14-29-20/h3-9,11,15,19H,10,12-14H2,1-2H3,(H,24,26)/t15-,19+/m0/s1
SMILES Code
C[C@@H](C(OCC1=CC=CC=C1)=O)NC([C@H](CC2=CC=C(OCO3)C3=C2)CSC(C)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
443.51
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Inoue M, Sasaki T, Takazawa H, Morita T, Narisawa A, Saito A, Midorikawa H, Nishijima M. Symptomatic vasospasm in elderly patients with aneurysmal subarachnoid hemorrhage: comparison with nonelderly patients. Acta Neurochir Suppl. 2013;115:281-4. doi: 10.1007/978-3-7091-1192-5_50. PubMed PMID: 22890682.
2: Ozdener F, Ozdemir V. Fasidotril Eli Lilly. Curr Opin Investig Drugs. 2003 Sep;4(9):1113-9. Review. PubMed PMID: 14582457.
3: Monteil T, Danvy D, Sihel M, Leroux R, Plaquevent JC. Strategies for access to enantiomerically pure ecadotril, dexecadotril and fasidotril: a review. Mini Rev Med Chem. 2002 Jun;2(3):209-17. Review. PubMed PMID: 12370063.
4: Sagnella GA. Vasopeptidase inhibitors. J Renin Angiotensin Aldosterone Syst. 2002 Jun;3(2):90-5. Review. PubMed PMID: 12228848.
5: Laurent S, Boutouyrie P, Azizi M, Marie C, Gros C, Schwartz JC, Lecomte JM, Bralet J. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension. 2000 May;35(5):1148-53. PubMed PMID: 10818079.
6: Fasidotril. Aladotril, alatriopril, BP 1137. Drugs R D. 1999 Apr;1(4):346-7. PubMed PMID: 10566060.
7: Marie C, Mossiat C, Gros C, Schwartz JC, Lecomte JM, Bralet J. Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction. Cardiovasc Res. 1999 Mar;41(3):544-53. PubMed PMID: 10435026.
8: Hu K, Ertl G. Potential role of mixed ACE and neutral endopeptidase inhibitor in the treatment of heart failure. Cardiovasc Res. 1999 Mar;41(3):503-5. PubMed PMID: 10435019.
9: Marie C, Mossiat C, Lecomte JM, Schwartz JC, Bralet J. Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction. J Pharmacol Exp Ther. 1995 Dec;275(3):1324-31. PubMed PMID: 8531099.
